The Executive Board of the Wyss Center for Bio and Neuroengineering, a non-profit research center, is pleased to announce the appointment of Prof. Dr. med. Erwin Böttinger as its new Chief Executive Officer.
Wyss Center Geneva Appoints Erwin Böttinger as new Chief Executive Officer Read More »
RELIEF THERAPEUTICS Holding SA announces the appointment of world-renowned gene therapy pioneer Guangping Gao, Ph.D. as the chair of the Company’s newly formed scientific advisory board.
Innate Pharma SA announced that it has entered into an exclusive license agreement with Takeda under which Innate grants Takeda exclusive worldwide rights to research and develop antibody drug conjugates using a panel of selected Innate antibodies against an undisclosed target, with a primary focus in Celiac disease.
ANGLE plc, a world-leading liquid biopsy company, will be releasing its preliminary results for the year ended 31 December 2022 on Friday 21 April 2023.
Angle PLC Announces Notice of Preliminary Results and Webcast Read More »
REGiMMUNE Limited, a biotech company focused on creating innovative immunotherapies for immune disorders and cancer, and San Fu Biotech, a subsidiary of San Fu Chemical Co., Ltd. have entered a licensing agreement to develop and commercialize RGI-2001 for the prophylaxis of acute Graft-versus-host disease in major Asian countries.
Medtronic plc and DaVita Inc. announced the launch of Mozarc Medical—an independent new company committed to reshaping kidney health and driving patient-centered technology solutions.
AnPac Bio-Medical Science Co., Ltd. announced that it has entered into a securities purchase agreement with certain institutional investors to purchase $3.0 million of its American Depositary Shares, pre-funded warrants to purchase ADSs and warrants to purchase ADSs in a registered direct offering.
AnPac Bio-Medical Science Announces Pricing of $3.0 Million Registered Direct Offering Read More »
Mabwell, an innovative biopharmaceutical company with the layout of whole industry chain, announced that the Denosumab solution for injection, which is developed by its wholly-owned subsidiary T-mab, has been formally approved for marketing by the National Medical Products Administration .
The World’s Second Approved Biosimilars of Denosumab (MAILISHU) Read More »
With several recent milestones, Intellia Therapeutics is setting a solid foundation for gene editing in rare diseases with an eye toward broader patient populations.
Intellia Seeks to Broaden Gene Editing’s Potential with Full-Spectrum Approach Read More »
En este Short os hablamos del origen del agua como la que se halla presente en planetas como la Tierra. …
